Gentian Diagnostics delivered 13% organic revenue growth and a strong EBITDA margin, driven by robust product and US sales, while proposing its first dividend and advancing its NT-proBNP pipeline. Cystatin C sales declined due to China, but long-term outlook remains positive.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.